Apixaban for the Prevention of Latent Biological Valve Thrombosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE4

Total Enrollment

166 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-12-31

Study Completion Date

2025-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Background: The optimal antithrombotic strategy early after aortic valve replacement surgery with a biological valve remains controversial due to lack of high-quality evidence. Either oral anticoagulants or acetylsalicylic acid should be considered for the first three months. Hypo-attenuated leaflet thickening on cardiac compute tomography has been associated with latent bioprosthetic valve thrombosis and may be prevented with anticoagulation. The investigators hypothesize that anticoagulation with apixaban is superior to single antiplatelet therapy with acetylsalicylic acid in reduction of hypo-attenuated leaflet thickening of bioprosthetic valves after aortic valve replacement.

Methods: In this prospective, open-label, randomized trial patients without an indication for oral anticoagulation undergoing isolated aortic valve replacement surgery with novel rapid-deployment bioprosthetic valves will be randomized. The treatment group will receive 5 mg of apixaban twice a day for the first three months and 100 mg of acetylsalicylic acid thereafter. The control group will have 100 mg of acetylsalicylic acid once a day indefinitely. After the three-month treatment period a contrast enhanced electrocardiogram-gated cardiac computed tomography will be performed to identify hypo-attenuated leaflet thickening of the bioprosthetic valve. The primary objective of the study is to assess possible superiority of the treatment group in the prevention of hypo-attenuated leaflet thickening three months after randomization. Secondary objective is to assess possible noninferiority for safety of apixaban-based strategy when compared to acetylsalicylic acid at three months.

Discussion: Antithrombotic therapy after aortic valve replacement surgery is used to prevent valve thrombosis and systemic thromboembolism. Latent bioprosthetic valve thrombosis is a precursor of clinically significant prosthetic valve dysfunction or thromboembolic event. The hallmark feature of latent bioprosthetic valve thrombosis is hypo-attenuated leaflet thickening on cardiac computed tomography. Subclinical leaflet thrombosis occurs frequently in bioprosthetic aortic valves, more commonly in transcatheter than in surgical valves. There is no evidence on the effect of direct oral anticoagulants on the incidence of hypo-attenuated leaflet thickening after surgical aortic valve replacement with rapid deployment bioprostheses.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Evolution of Coagulation Activity in Non Valvular Atrial Fibrillation Patients Under Apixaban

NCT03136510

Coagulation Disorder Non Valvular Atrial Fibrillation

TERMINATED NA

Antiplatelet Therapy for Patients Undergoing Transcatheter Aortic Valve Implantation

NCT02247128

Aortic Valve Disease Myocardial Infarction Stroke +1 more

COMPLETED PHASE4

Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation

NCT00412984

Atrial Fibrillation Atrial Flutter

COMPLETED PHASE3

Short Versus Long Antiplatelet Therapy After TAVI

NCT06518317

Transcatheter Aortic Valve Replacement

RECRUITING PHASE3

Rivaroxaban or Aspirin for Biological Aortic Prosthesis

NCT02974920

Aortic Stenosis Aortic Regurgitation Thrombosis

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aortic Valve Replacement Antithrombotic Therapy Bioprosthetic Valve Thrombosis Rapid Deployment Valves

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention Arm

Patients randomised to the intervention arm will receive an open-label dose adjusted apixaban twice a day. The treatment will be continued for three months. After the tree-month treatment period apixaban will be stopped and acetylsalicylic acid will be started.

Group Type EXPERIMENTAL

Aortic valve replacement surgery

Intervention Type PROCEDURE

Patients undergoing first-time isolated aortic valve replacement with a rapid deployment biological prosthesis.

Computed tomography

Intervention Type DIAGNOSTIC_TEST

All the study patients will undergo a computed tomography imaging to assess for hypo-attenuated leaflet thickening and reduced leaflet mobility of the biological prosthesis following the three-month treatment period.

Echocardiography

Intervention Type DIAGNOSTIC_TEST

All the study patients will undergo a transthoracic echocardiography before hospital discharge and following the three-month treatment period.

Control Arm

Patients assigned to the control arm will receive an open-label low dose acetylsalicylic acid indefinitely.

Group Type ACTIVE_COMPARATOR

Aortic valve replacement surgery

Intervention Type PROCEDURE

Patients undergoing first-time isolated aortic valve replacement with a rapid deployment biological prosthesis.

Computed tomography

Intervention Type DIAGNOSTIC_TEST

All the study patients will undergo a computed tomography imaging to assess for hypo-attenuated leaflet thickening and reduced leaflet mobility of the biological prosthesis following the three-month treatment period.

Echocardiography

Intervention Type DIAGNOSTIC_TEST

All the study patients will undergo a transthoracic echocardiography before hospital discharge and following the three-month treatment period.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Aortic valve replacement surgery

Patients undergoing first-time isolated aortic valve replacement with a rapid deployment biological prosthesis.

Intervention Type PROCEDURE

Computed tomography

All the study patients will undergo a computed tomography imaging to assess for hypo-attenuated leaflet thickening and reduced leaflet mobility of the biological prosthesis following the three-month treatment period.

Intervention Type DIAGNOSTIC_TEST

Echocardiography

All the study patients will undergo a transthoracic echocardiography before hospital discharge and following the three-month treatment period.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women aged 65 or older with aortic valve stenosis undergoing successful isolated first-time aortic valve replacement with a rapid deployment bioprosthetic valve
* Signed informed consent to participate in the research

Exclusion Criteria

* Indication for long-term use of anticoagulant therapy
* Indication for dual antiplatelet therapy
* Contraindication to anticoagulation or antiplatelet therapy
* Inability to start the study drug within the planned randomization period
* History of atrial fibrillation
* Known hemorrhagic diathesis
* Presence of other significant heart pathology
* Prior open-heart surgery
* Presence of liver failure or other coagulopathy
* Aortic valve infective endocarditis
* Severe renal failure
* Allergy to iodine contrast

Minimum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No